Meeting
2018 Gastrointestinal Cancers Symposium
Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study.
Authors
Helen Guo
Cancer Care Ontario, Toronto, ON, Canada
Helen Guo , Jaclyn Marie Beca , Ruby Redmond-Misner , Wanrudee Isaranuwatchai , Lucy Qiao , Craig Earle , Scott R. Berry , James Joseph Biagi , Stephen Welch , Brandon Matthew Meyers , Nicole Mittmann , Natalie G. Coburn , Aliya Pardhan , Jessica Arias , Deborah Schwartz , Scott Gavura , Leta Marie Forbes , Robin McLeod , Erin Diane Kennedy , Kelvin K. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 375)
DOI
10.1200/JCO.2018.36.4_suppl.375
Abstract #
375
Poster Bd #
H12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
2017 Gastrointestinal Cancers Symposium
Effect of advanced age, elevated bilirubin, and disease extent on outcomes of unresectable pancreatic cancer (UPC) patients receiving first-line chemotherapy: A population-based study.
First Author: Hannah Marie Cherniawsky
Poster
2017 Gastrointestinal Cancers Symposium
Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Hui-Li Wong
Poster
2015 Gastrointestinal Cancers Symposium
A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F).
First Author: Austin G. Duffy